• Genentech reported its Phase III CELESTIMO trial met the primary endpoint in relapsed or refractory follicular lymphoma.
• The Lunsumio-lenalidomide regimen extended the time patients lived without disease worsening versus Rituxan-lenalidomide.
• Overall survival data were not yet mature at the interim analysis.
• Safety matched known profiles for the drugs with no new signals, supporting an outpatient, simplified dosing approach.
• Results have not been presented yet; data are slated for an upcoming medical meeting, with regulatory submissions planned.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genentech Inc. published the original content used to generate this news brief on September 16, 2026, and is solely responsible for the information contained therein.